Skip to content

Mechanistic Underpinnings of Preeclampsia

Mechanistic Underpinnings of Preeclampsia

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06567899
Acronym
MUP
Enrollment
500
Registered
2024-08-23
Start date
2026-07-25
Completion date
2029-12-31
Last updated
2025-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preeclampsia

Brief summary

Preeclampsia is a dreadful disease with significant morbidity and mortality. Despite decades of research, we still need a proper diagnostic test or therapeutic option to treat this disorder. The proposed study will determine the diagnostic value of PBMC-secreted sFlt1 and determine the molecular mechanisms involved in its secretion. The molecular mechanisms can be novel therapeutic targets to treat this disorder.

Interventions

None listed

Sponsors

University of Arizona
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Healthy Adults: • Healthy non-pregnant with previous normal pregnant women Non-Health Adults: • Patients will be admitted with the diagnosis of preeclampsia according to the internationally accepted definition of preeclampsia: Blood pressure measurement of 140/90 mm Hg or an increase of 30 mm Hg systolic or 15 mm Hg diastolic over baseline values on at least two occasions, six or more hours apart and proteinuria; 300 mg/24 hour after 20th week of gestation. Pregnant Women: Groups 3 - 6 will include pregnant women at different trimesters. Criteria common to all groups: * The study will be conducted only in females aged 18 or above. * Patients in all the groups will be matched for age, which will be 18 or above. * Women will be matched for body mass index; criteria for normal body mass index will be used based on the Center for Disease Control and Prevention Guidelines. * Patients with premature rupture of the membrane, non-preeclamptic preterm labor, IUGR, placental abruption, twin? Any other complications during the pregnancy will be excluded from the study. * Patients with any evidence of genetic or non-genetic malformations of the fetus will be excluded from the study. * The study will be conducted on women who are non-smokers and do not consume alcohol or recreational drugs. * The study will be conducted only on primigravida females to minimize phenotyping variability. * The women with a known history of any chronic disorder, including but not limited to hypertension, diabetes, pulmonary, renal, cardiac, or cerebrovascular disorders, will be excluded from the studies.

Design outcomes

Primary

MeasureTime frameDescription
sFLT1 levelsOutcome will be measured at 12 weeks, 24 weeks and 36 weeks of pregnancy.sFLT1 levels in preeclampsia should be higher than normal pregnancy.

Contacts

Primary ContactRavi Goyal, MD, PhD
goyalr@arizona.edu520-626-5573

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026